Credit Suisse Ag Next Cure, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$9.81 - $13.88 $136,417 - $193,015	-13,906 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$9.47 - $12.43 $7,509 - $9,856	793 Added 6.05%	13,906 $151,000
Q3 2020 Nov 13, 2020	BUY	$8.15 - $21.17 $106,870 - $277,602	13,113 New	13,113 $115,000
Q2 2020 Aug 12, 2020	SELL	$21.19 - $40.2 $146,592 - $278,103	-6,918 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$32.32 - $58.37 $102,422 - $184,974	-3,169 Reduced 31.42%	6,918 $256,000
Q4 2019 Feb 12, 2020	BUY	$25.0 - $92.22 $252,175 - $930,223	10,087 New	10,087 $568,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.